Company
Incyclix Bio
ADVANCING NOVEL CDK INHIBITORS FOR CANCER PATIENTS
Also known as INCYCLIX BIO, LLC
- Business model
- B2B
- Headquarters
- Research Triangle Park, NC, United States
- Legal name
- INCYCLIX BIO, LLC
- incyclixbio.com (opens in a new tab)
- LinkedIn (opens in a new tab)
- X (opens in a new tab)
- Press page (opens in a new tab)
- Careers (opens in a new tab)
Claim, correct or request removal
Record updated 28 September 2026
About
Incyclix Bio is a cell cycle company developing precision therapies for cancer, led by a selective CDK2 inhibitor nearing clinical stage.
Funding snapshot
- Total raised
- $46.2MSum of rounds, as of 2026-09-18Source (opens in a new tab)
- Latest round
- Series B, $5M2026-04-08
Funding rounds
- Series B
- $5M2026-04-08, Company stated
- Series B
- $11.2M2025-08-25, Company stated, 4 investors
- Series B
- $30M2022-03-31, Company stated
- Round, 2022
- $15M2022-02-22, SEC form D sold, 5 investors
Products
- Web
- INX-315
Loading relationship preview